Dry eye syndrome therapeutics currently exhibits a proliferating pipeline of 50+ therapeutic candidates.
According to the research, most of the therapeutic drug candidates are being developed for topical administration. It has been found that topical route of administration is easy to use, non-invasive, and ensures high level of patient satisfaction, and therefore, improves patient compliance.
The companies who are involved in developing therapeutics for dry eye syndrome have shown positive clinical results in the various phases of drug development. For instance, HL036, an anti- tumor necrosis factor (TNF) biobetter antibody, is being developed by HanAll BioPharma in collaboration with Harbour BioMed for the treatment of inflammatory diseases. The results from the Phase II clinical trials of the drug candidate, showed statistically significant improvement of the symptoms, in the patients with dry eye syndrome.
Moreover, in September 2017, Redwood Pharma AB contracted the Swiss contract research organization (CRO) CROss Alliance for the management of a clinical Phase II clinical trial of the drug candidate, RP101, in patients with chronic dry eye disease.
TopiVert Pharma Limited, Redwood Pharma AB, HanAll BioPharma, Takeda Pharmaceutical Company Limited, Mitotech SA, Harbour BioMed, and Samjin Pharm Co. Ltd. are some of the key companies involved in the development of dry eye syndrome therapeutics.
No comments:
Post a Comment